Yahoo Finance EN

Pfizer Could Hit $36 by Year-End as Analysts See 2-to-1 Payoff on Key Prostate Cancer Trial

Mar 24, 2026 &03522424202631; 14:52 UTC finance.yahoo.com Trending 4/5

Read original on finance.yahoo.com ↗

↗

Positive for markets

Sentiment score: +62/100

Moderate impact Medium-term (weeks)

WHAT THIS MEANS

Pfizer receives analyst upgrade targeting $36 year-end price on positive prostate cancer trial expectations, offering 2-to-1 payoff potential. Fresh catalyst with clear upside thesis, but market context shows S&P 500 slightly negative and VIX elevated, suggesting cautious sentiment.

AI CONFIDENCE

68% High

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↑

PFE

PFEStock

Expected to rise

Fresh analyst upgrade with $36 year-end target implies 2-to-1 payoff on successful prostate cancer trial; positive catalyst not yet fully absorbed by market given recent publication (18 min ago)

⇅

S&P 500

^GSPCIndex

High volatility expected

Pharma strength offset by broader market weakness (-0.09%) and elevated VIX (26.18); sector rotation risk

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

PFE shows genuine upside catalyst with fresh analyst support, but elevated VIX and negative market breadth create execution risk. Consider entry on any dip; avoid chasing if stock already moved >1.5% higher from open. Risk/reward favors long bias but position size accordingly given macro uncertainty. [MOVE:2.8%]

KEY SIGNALS

Fresh analyst upgrade (18 min old)Key clinical trial catalyst (prostate cancer)2-to-1 payoff ratio suggests material upsideBroader market headwinds (VIX +0.11%, SPX -0.09%)Year-end target provides medium-term horizon

SECTORS INVOLVED

HealthcarePharmaceuticals

Analysis generated on Mar 24, 2026 at 15:10 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Yahoo Finance. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Pfizer Could Hit $36 by Year-End as Analysts See 2-to-1 Payoff on Key Prostate Cancer Trial

RELATED INTELLIGENCE